Navigation Links
OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
Date:7/14/2008

bination with docetaxel retreatment have indicated that OGX-011 may help restore tumor sensitivity to docetaxel and may improve overall survival for second-line therapy."

The planned initiation of this Phase 3 trial is supported by encouraging preliminary Phase 2 data that were presented at the 2008 annual meeting of the American Society of Clinical Oncology (ASCO). These preliminary data are derived from a Phase 2 study evaluating 42 patients with HRPC who had received first-line docetaxel therapy and required second-line chemotherapy: 22 patients were treated with mitoxantrone plus OGX-011 and 20 patients with docetaxel retreatment plus OGX-011. While follow up on surviving patients is still ongoing, the following preliminary findings were reported:

- Survival continued to be better than expected based on previously

published reports: With a median follow-up of 17.2 months following the

start of second-line chemotherapy, median survival has been estimated

at 11.4 months in the mitoxantrone plus OGX-011 group and 14.7 months

in the docetaxel retreatment plus OGX-011 group. These data compare

favorably with published results reporting median survivals at

approximately 10 months for HRPC patients receiving second-line

chemotherapy without OGX-011.

- In addition, average serum clusterin levels during treatment were

predictive of survival, with low-average levels predicting median

survival time of 14.7 months compared to high-average levels predicting

median survival time of 5.5 months. These data suggest that a reduction

in clusterin levels may improve survival.

About OGX-011

OGX-011 is designed to block production of clusterin, a cell survival protein that is over-produced in several cancer indications and in response to many cancer treatments. Increased clusterin production is observed in many human cancers, including prostate, non-small c
'/>"/>

SOURCE OncoGenex Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. OncoGenex increases economic interest in lead cancer drug OGX-011
2. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
3. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
4. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
5. CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina
6. Epeius Biotechnologies Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for the Treatment of Osteosarcoma
7. Edison Pharmaceuticals Receives Commendation From the City of San Jose
8. GeneraMedix Inc. Receives Approval for Epoprostenol for Injection 1.5 mg
9. Microfluidic Systems Receives Continued Funding From the Department of Homeland Security (DHS) Toward the Commercial Production of Autonomous Airborne Pathogen Detection Systems
10. Par Pharmaceutical Receives Final Approval to Market Generic Marinol(R) CIII (Dronabinol) Capsules
11. Indevus Receives Approvable Letter from FDA for NEBIDO(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... Each year in the US, ... attention. In the military, burn injury is a ... medical care. More than 800 service members sustained ... heal slowly, remain inflamed and often become infected, ... and functionally damaging. While developments in supportive care ...
(Date:9/29/2014)... at the forefront of diagnostics today, with imaging ... tomography), scanning, and NMR (nuclear magnetic resonance) increasing ... problems of image resolution and quality still limit ... tissue. A solution is hyperpolarization, which involves injecting ... quality by following the distribution and fate of ...
(Date:9/29/2014)... conflicts in Iraq and Afghanistan, more than 300,000 soldiers ... injury caused by exposure to bomb blasts and ... Symptoms of traumatic brain injury can range from the ... severe impairments in memory and cognition. , Since ... critical importance and complexity of this problem, and has ...
(Date:9/29/2014)... Va. , Sept. 29, 2014  Ten ... the fields of cartilage repair, regeneration, allograft reconstruction ... from around the world gathered to discuss the ... Health Institute of Regenerative Medicine symposium, Cartilage ... . Topics included Orthopedic Biosurgery, Minced Juvenile Allograft, ...
Breaking Biology Technology:Faster Healing with Fewer Scars 2A safer approach for diagnostic medical imaging 2A safer approach for diagnostic medical imaging 3Modeling shockwaves through the brain 2Modeling shockwaves through the brain 3Modeling shockwaves through the brain 4World Renowned Experts Discuss Future Of Cartilage Regeneration 2World Renowned Experts Discuss Future Of Cartilage Regeneration 3
... Dendreon Corporation,(Nasdaq: DNDN ) today announced ... NEUVENGE, an investigational active cellular immunotherapy, in the,August ... The article highlights,the safety profile, immune response and ... cancer who have failed standard,therapy. "In addition ...
... Inc., a biotechnology company developing pharmaceutical products for ... dollar financing deal. The majority of the funding, ... the remainder was borrowed from the Madison Development ... Funds, a private investment firm. The funds raised ...
... more than a marketing campaign and the involvement of ... managers, senior executives and middle managers responsible for creating ... play a vital role in marketing the brand. Employees ... work. , ,Be Your Message. Employer brand building ...
Cached Biology Technology:Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients 2Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients 3Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients 4Quintessence Secures Financing 2Quintessence Secures Financing 3Employer Brands Require More Than Slick Marketing 2
(Date:9/29/2014)... A University of Texas at Arlington research team says ... built in their lab could open doors for homeland ... be published in the Oct. 1 issue of ... and his co-authors describe a new method to fabricate ... and oxygen until a transparent ceramic is formed. ...
(Date:9/29/2014)... has received a five-year, $6 million grant for ... evaluation and development of safe and effective treatments ... from the National Institutes of Health, National Institute ... for Medication Development for Cocaine Use Disorder to ... guide decisions on moving forward with more expensive ...
(Date:9/29/2014)... For decades, planetary geologists have speculated that glaciers ... 2000-mile-long chasm that constitutes the Grand Canyon of ... that might have been carved by past glaciers ... observations have remained highly controversial and contested. ... College and the Freie Universitaet Berlin has identified ...
Breaking Biology News(10 mins):UT Arlington researchers develop new transparent nanoscintillators for radiation detection 2UT Arlington researchers develop new transparent nanoscintillators for radiation detection 3New VCU center to target cocaine addiction 2Glaciers in the Grand Canyon of Mars? 2Glaciers in the Grand Canyon of Mars? 3Glaciers in the Grand Canyon of Mars? 4Glaciers in the Grand Canyon of Mars? 5Glaciers in the Grand Canyon of Mars? 6Glaciers in the Grand Canyon of Mars? 7Glaciers in the Grand Canyon of Mars? 8Glaciers in the Grand Canyon of Mars? 9
... (Santa Barbara, Calif.) An international team of researchers ... that happens in virtually every cell of our bodies. ... folded chains of amino acids assume their specific shapes, ... widely: In the human body, proteins fold to become ...
... family history of liver cancer is reported to increase risk ... findings published in the May issue of Hepatology , ... Liver Diseases. The study also shows 70-fold elevated risk of ... markers for hepatitis B (HBV) or hepatitis C (HCV). ...
... Princeton University researchers have observed a self-degradation response to ... provide new answers to lingering questions among scientists about ... that depression is not solely linked to the neurotransmitter ... PLoS ONE , researchers based in the lab of ...
Cached Biology News:In protein folding, internal friction may play a more significant role than previously thought 2Family history of liver cancer increases risk of developing the disease 2Yeast cell reaction to Zoloft suggests alternative cause, drug target for depression 2Yeast cell reaction to Zoloft suggests alternative cause, drug target for depression 3Yeast cell reaction to Zoloft suggests alternative cause, drug target for depression 4
... xi 2-D system runs both gel dimensions in the ... can be separated in a single run using the ... in much the same manner as the slab gel ... slab gels may be cast in the casting stand. ...
... Application Series are a line of ... provide fast and reliable automated solutions ... robust "automation-friendly" building blocks, Caliper has ... less than conventional approaches, take up ...
... 2-Methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]pyrimidine-4-one White solid. ... A brain-permeable and water soluble pyrimidinone compound ... + -competitive inhibitor of PARP (IC 50 ... for rhPARP1 and rmPARP2, respectively) with little ...
...
Biology Products: